Astellas Pharma

(OTC) ALPMY

Current Price$14.98

Market Cap$26.37B

Since IPO (2008)+101%

5 Year+14%

1 Year+60%

1 Month-11%

Astellas Pharma Financials at a Glance

Market Cap

$26.37B

Revenue (TTM)

$2.27T

Net Income (TTM)

$309.12B

EPS (TTM)

$1.08

P/E Ratio

13.59

Dividend

$0.25

Beta (Volatility)

0.31 (Low)

Dividend

$0.25

Beta (Volatility)

0.31 (Low)

Price

$14.98

Volume

37,095

Open

$14.93

Price

$14.98

Volume

37,095

Open

$14.93

Previous Close

$14.72

Daily Range

$14.89 - $15.00

52-Week Range

$9.09 - $17.35

Dividend

$0.25

Beta (Volatility)

0.31 (Low)

Price

$14.98

Volume

37,095

Open

$14.93

Previous Close

$14.72

Daily Range

$14.89 - $15.00

52-Week Range

$9.09 - $17.35

ALPMY News

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Astellas Pharma

Industry

Pharmaceuticals

Sector

Health Care

Employees

13,643

CEO

Naoki Okamura

Website

www.astellas.com

Headquarters

Tokyo, 103-8411, JP

ALPMY Financials

Key Financial Metrics (TTM)

Gross Margin

76%

Operating Margin

19%

Net Income Margin

14%

Return on Equity

18%

Return on Capital

17%

Return on Assets

Earnings Yield

7.36%

Dividend Yield

1.71%

Payout Ratio

46.68%

Stock Overview

Market Cap

$26.37B

Shares Outstanding

1.79B

Volume

37.09K

Avg. Volume

154.89K

Financials (TTM)

Gross Profit

$1.69T

Operating Income

$445.01B

EBITDA

$651.34B

Operating Cash Flow

$600.40B

Capital Expenditure

$61.20B

Free Cash Flow

$539.20B

Cash & ST Invst.

$282.83B

Total Debt

$247.02B

Astellas Pharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2026YOY CHG

Revenue

$647.49B

+41.0%

Gross Profit

$457.56B

+19.6%

Gross Margin

70.67%

N/A

Market Cap

$26.37B

N/A

Market Cap/Employee

$1.79M

N/A

Employees

14,754

N/A

Net Income

$57.97B

-22.6%

EBITDA

$52.63B

-151.7%

Quarterly Fundamentals

Name

Q4 2026YOY CHG

Net Cash

$35.81B

+105.8%

Accounts Receivable

$765.07B

+21.0%

Inventory

$332.45B

+11.8%

Long Term Debt

$321.39B

-43.1%

Short Term Debt

$247.02B

-7.3%

Return on Assets

8.17%

N/A

Return on Invested Capital

17.24%

N/A

Free Cash Flow

$191.01B

+109.0%

Operating Cash Flow

$207.50B

+105.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ORINYOrion Oyj

ORINYOrion Oyj$37.99+0.00%

OTSKFOtsuka Holdings Co., Ltd.

OTSKFOtsuka Holdings Co., Ltd.$64.57+0.00%

WXIBFWuXi Biologics (Cayman) Inc.

WXIBFWuXi Biologics (Cayman) Inc.$4.30+0.00%

WXXWYWuXi Biologics (Cayman) Inc.

WXXWYWuXi Biologics (Cayman) Inc.$8.58+1.06%

SAUHFStraumann Holding AG

SAUHFStraumann Holding AG$106.03-1.61%

GNMSFGenmab A/S

GNMSFGenmab A/S$264.64+1.94%

GIKLYGrifols, S.A.

GIKLYGrifols, S.A.$5.30+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$17.02+0.07%

VNETVnet Group

VNETVnet Group$11.37+0.26%

NIONio

NIONio$6.48+0.07%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.04+0.01%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.69-0.01%

BABAAlibaba Group

BABAAlibaba Group$143.63+0.07%

NVDANvidia

NVDANvidia$227.16+0.03%

Questions About ALPMY

What is the current price of Astellas Pharma?

Astellas Pharma is trading at $14.99 per share.

What is the 52-week range for Astellas Pharma?

Over the past 52 weeks, Astellas Pharma has traded between $9.09 and $17.35.

How much debt does Astellas Pharma have?

As of the most recent reporting period, Astellas Pharma reported total debt of $3.56B.

How much cash does Astellas Pharma have on hand?

Astellas Pharma reported $1.77B in cash and cash equivalents in its most recent financial results.

What is Astellas Pharma’s dividend yield?

Astellas Pharma currently has a dividend yield of 1.71%.

Astellas Pharma

Astellas Pharma Financials at a Glance

ALPMY News

Why It's So Dang Hard to Value Biotech Deals

What Pfizer Gets in Its $14 Billion Medivation Deal

What Sent Medivation, Inc.'s Shares Soaring 25.1% In April

Sanofi's Bid for Medivation Is Too Low

J&J's Q1 Results Suggest More Upside for Medivation, Inc.

How Biotech Is Getting Berned by Sanders

Why Medivation Shares Are Tanking Today

Medivation Inc. Stock Is Rising Today -- Here's Why

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Astellas Pharma

ALPMY Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Astellas Pharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ALPMY

What is the current price of Astellas Pharma?

What is the 52-week range for Astellas Pharma?

How much debt does Astellas Pharma have?

How much cash does Astellas Pharma have on hand?

What is Astellas Pharma’s dividend yield?

Premium Investing Services